Dealmaking is essential to the business of drug development. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. *Average returns of all recommendations since inception. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. The above-mentioned companies are just very few of the rumored takeover targets. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc. Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company. Example: +water -Europe There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. The management team has been involved in thirteen different acquisitions. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. Oncology and gene therapy were the subjects of acquisitions this year. The pipeline progress has been encouraging. Government. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. To make the world smarter, happier, and richer. Pharma giant Pfizer recently. Use a + to require a term in results and - to exclude terms. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. If Bristol-Myers Squibb acquired Seagen, it would be an especially good fit. Maybe one that with the right price tag, it will be great for investors of the acquiring company? That's the downside there. 2023 InvestorPlace Media, LLC. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. Here's a look at the 10 top takeover targets. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. Copyright Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. The uptake of all these products has been good. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. Go and get the Biotech Investments HOT STOCK REPORT. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. Global Blood Therapeutics ( GBT) - $9B. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. If you have an ad-blocker enabled you may be blocked from proceeding. Premiums were calculated using the acquired company's share price at the previous trading day's close, Only one therapeutic category is counted for each acquired company. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. While Some Have Learned From It, Others Wont. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. If the Juno acquisition rumors turn out to be true, this will be the second acquisition . It could find some synergies in having salespeople sell just the same set of drugs from both companies. Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. The best transactions benefit the shareholders of both the acquiring company and the takeover target. We first began to hear acquisition rumors in Antares in late 2011. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. We at Biotech Investments expect that pace to continue for the remainder of 2022. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. Price as of January 17, 2023, 4:00 p.m. Powered by Madgex Job Board Software. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. This therapeutic has been licensed to Swiss pharma giant Novartis. Cambridge, Massachusetts-based Crisprs lead asset CTX001 is in development for two indications beta thalassemia and sickle cell disease in collaboration with Vertex Pharma. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. However, the Company has turned down Elliott's recommendation. Antares Pharma. earnings call is. Mergers and acquisition (M&A) activity in India is heating up. Additionally, Pfizer has registered a website, Otrexyo.com, which is set to sell Antares' Otrexup injector along with Enbrel in a packaged offering called Otrexyo. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. It was also approved in the EU. Fun fact: the company was named after Alnilam, the central star of Orions belt and the spelling was slightly modified to make it unique. At the time, I was . Analysts, on average, see scope for about 90% upside for Mirati stock. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. The Company submitted a Marketing Authorization Application to the. Avulux is pleased to announce that Axon Optics is now part of the Avulux family. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. The stock has lost 14% of its value since February and trades around $80. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. One of the catalysts that could work in its favor is deal optimism. Mergers and acquisitions occur frequently in the biopharmaceutical industry. But Brian, is there a biotech buyout that you would really like to see? We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. Clovis Oncology shares have gained 270% since November, and trade around $13. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. Additionally, the database is limited to deals valued at a minimum of $50 million upfront. Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. AMRN closed Friday's trading at $24.12, up 4.92%. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. Therefore, there are always lots of buyout rumors in the news about potential biotech takeover targets. Any you had ideas about? The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. One of those stocks was. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. It's in phase 1, so we don't really know how well it works yet. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. To read this article on Zacks.com click here. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. To make the world smarter, happier, and richer. A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. quotes delayed at least 15 minutes, all others at least 20 minutes. This would be a similar strategy Voce followed with Obagi. Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. Get biopharma news like this in your inbox daily. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. Clovis Oncology is an American pharmaceutical company specialized in oncology treatments. Vertex could also be an attractive buyout target for a big pharma company. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. BioPharma Dive is tracking these deals below. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. The Motley Fool recommends Biogen and Gilead Sciences. Stay on top of what's happening at JPM. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. Additionally, Dan is a Scientist and inventor. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. I don't know, maybe they could out-license those. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . Politics. Copy and paste multiple symbols separated by spaces. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? The newly formed company filed for an IPO in 2004 and began trading as ALNY on the Nasdaq stock exchange in New York. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. I am not receiving compensation for it. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. 5. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. But I think there's also a good fit on Seagen's pipeline too. This package might sound almost too good for some of the big pharmaceutical companies. Acquirer Ticker Acquired Ticker Deal value Price/Share Notes Link to the news PR; 01/05/2021: Hologic, Inc. HOLX: Private-German co. $64M-leader in biopsy site markers: https://bwnews.pr/2L3d7lF: After a lengthy drought, could biotech M&A be on the upswing? In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. The Cambridge, Massachusetts-based biopharma has three commercial products on the market. These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. Miratis KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination for several cancer indications. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. Best Stocks & ETFs. M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. The quest behind the drive is to fill potential gaps in the pipeline. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. In 2003, Alnylam merged with the German pharmaceutical company, Ribopharma AG. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. All rights reserved. Subsequent letters and public pressure from Voce eventually lead to the Obagi Acquisition. On January 9, 2023, Biotech Acquisition Company (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the . If the letter of intent to acquire your company has been signed, you might be asking what happens next. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. You can incur substantial financial losses in any trade or investment. Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. 1125 N. Charles St, Baltimore, MD 21201. Orelli: I think a pharma that wanted a lot of cash flow, but also wanted to boost up their pipeline, Vertex probably has more external deals than it has internal candidates. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. Scott has long positions in 3 companies mentioned in this article. After a rather bumpy start with disappointing sales numbers in 2019 and 2020, CAPLYTA net product revenues for the second quarter 2022 showed a 190% increase as compared to the same period in 2021 and a 58% increase over the first quarter 2022. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Pharma giant Pfizer recently announced that it will acquire Arena. 6. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. Some have merit and turn out to be true, while others turn out to be false and without merit. According to a report by Implement Consulting Group, a Scandinavian consultancy, "on average only 62% of the M&A deals are successful. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. These symbols will be available throughout the site during your session. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Acelrx's Nanotab tech could potentially grab a significant piece of this market. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. With focus on discovery, development and commercialization of a strong product portfolio, collaborating with industry-leading partners such as Novartis and Sanofi Genzyme, and an outstanding therapeutics pipeline, Alnylam is one of those biotech gems big pharma companies have on their radar. Which company is going to get bought? This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. Written by Scott Matusow. Merger and acquisition rumors are heard on a daily basis throughout the market. Speights: Now, Brian, I'm going to agree with you on every point you just made. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Furthermore, Antares and Pfizer entered into a collaboration in December 2011 for a yet still undisclosed product. Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. They could develop that in combination. I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. . Alexion Pharmaceuticals. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. Copyright 2023 InvestorPlace Media, LLC. Subscribe to BioPharma Dive. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. Equipped with a Bachelors degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. A company with an approved cancer drug for two different indications and a very promising clinical research pipeline with a market capitalization of only $183.3 million? Cash position at the end of the fiscal year was at $1.52 billion. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). As part of the acquisition of Celgene, the . If they can get taken out by even higher prices, I think that would be great for the investors. Alnylam currently carries a Zacks Rank #3 (Hold). Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. Ionis (NASDAQ:IONS) is commercial-stage biopharma developing RNA-targeted therapy using antisense technology that can control gene expression in a cell using antisense oligonucleotides (ASO). Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. Please. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. ATRS. RTTNews->. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. Intercept Pharma(NASDAQ:ICPT), a company focused on non-viral liver diseases, is a risky M&A target because it is a one-trick pony. In addition, the American company has several commercial and research successes, including recent positive Phase 3 clinical trial data for its ATTR amyloidosis drug ONPATTRO (Patisiran). The reason is that their deal is for an over the counter product that Pfizer has in its inventory. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. CRISPRs lead product candidate, CTX001, is an investigational, autologous, gene-edited hematopoietic stem cell therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . Brian, what are some acquisitions that you'd like to. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. Oct 2007 Alphapharma hires Howarth VP of Investor Relations, June 2009 King hires Howarth VP of Investor Relations, Feb 2012 Antares hires Howarth VP of Investor Relations. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. We expect approval for ValRox in Europe and the U.S. in the next few months. No. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. Mergers & Acquisitions (M&As) are back in focus in the biotech sector as Merck MRK recently acquired Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 . The Motley Fool has a disclosure policy. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. Medarex bought out GenPharm for $65M. Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. I own Seagen. Invest better with The Motley Fool. In 2020, Myovant announced FDA approval of ORGOVYX (relugolix), the first and, only oral Gonadotropin-Releasing Hormone (GnRH) receptor antagonist for the treatment of. In the business of drug development, deals can be just as important as scientific breakthroughs. Someone is "mistaken" here. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. (2016). 13. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. Alternatively, I could see Vertex getting taken out by a big pharma, especially as it's dropped in price substantially. All rights reserved. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." We've just talked about two deals that have been announced this week. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. Disclosure: I am long ATRS, SLTM, ACRX. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. We first began to hear acquisition rumors in Antares in late 2011. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). There were a few, but not as many. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. Takeover rumors initially swirled around Clovis Oncology in 2013 when Rubraca, was in clinical trial stage. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Now, let's take a speculative twist in our discussion about acquisitions. 12. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Often, these deals focused on cancer, rare diseases and immune system disorders areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. 4. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. BioSpace is covering all the key announcements all week. Later, Bristol-Myers Squibb for $2.4B. RTTNews.com for Scott is an independent investor/writer/trader and team leader of StockMatusow.com. In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. They are my opinions only. BioMarin is almost every analyst's favorite takeover candidate. Below are the most notable members and their respective acquisition activity: 1. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. Is It Too Late to Buy Vertex Pharmaceuticals Stock? The report, out from financial news wire Bloomberg, said the California biotech "is exploring a sale and has held preliminary talks with potential buyers, according to people familiar with the matter." Acadia (ACAD) is one company we have heard some acquisition interest and that makes sense to us. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. 8. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. Written by BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). Biotech M&A With a Slow Start in 2020: More Deals to Follow? Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. Learn More. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. 06-01-2023. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. Want the latest recommendations from Zacks Investment Research? BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. Nasdaq The Company submitted a Marketing Authorization Application to the. Antares Pharma (ATRS). Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. Biotech/FDA. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Otrexyo is a registered trademark of Pfizer. 1985 - 2023 BioSpace.com. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the . Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. . In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. Enclose phrases in quotes. Analysts, on average, predict over 75% upside for Crispr shares. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Someone is "mistaken" here. I have no business relationship with any company whose stock is mentioned in this article. Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN)announced today that the Company has entered into a binding agreement (the Arrangement Agreement) with Shockwave Medical, Inc. (Shockwave), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the Common Shares) of the Company (the Transaction). 10. Tripos International bought out Pharsight for $57M. 1. In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. Just recently, Bayer bought out Conceptus for $1.1B. Trading stocks is risky -- always be sure to know and understand your risk tolerance. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. The Motley Fool has a disclosure policy. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. FTX Fooled the World. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. Alnylam stock has a market capitalization of over $20 billion. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. INCY has gained 43% year-to-date and trades around $91. And how much are they willing to spend? For this story, BioPharma Dive looked only at companies developing human medicines. ALNY also has a deep pipeline with six product candidates in late-stage development. In case of a buyout, investors often benefit of a massive premium. Sanofi has been quite active on the M&A front this year. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. But that deadline has long passed. todd levin composer, how to remove apple pay from doordash, who cleans upstairs at graceland, who fasted for 14 days in the bible, jake matthews ufc career earnings, kindly provide your concurrence reply, cameron diaz house long beach, cracker: a new terror, shed for rent ballarat and surrounds, funeral homes in west liberty, ky, national library singapore architecture, why did johnny sequoyah leaves american housewife, paroles de la chanson le monde a besoin d'amour, what happened to aiden on body of proof, dayton fan company website, Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer well a! Pharmaceutical companies of todays Zacks # 1 Rank ( strong Buy ) stocks here selecting it and Enter/Return! Should consider buying CRISPR Therapeutics and Vertex Pharmaceuticals happens next 101 in and! Most notable members and their respective acquisition activity: 1 technology that allows precise, directed to! Will provide Sanofi access to our top analyst recommendations, in-depth research, investing resources and! Picking up biotech stocks with exceptional future perspectives and some of the rumored takeover targets 2021, reflecting antitrust! Owns shares of and recommends CRISPR Therapeutics ( CRSP 3.66 % ) has. Strong merit with Vertex pharma buyout and force would-be acquirers to offer more lock... Talked about two deals that have been hearing some strong acquisition rumors in Antares in late 2011, and... See take place in the biopharmaceutical world are mergers & acquisitions ( &. In your inbox daily serious diseases using its proprietary CRISPR/Cas9 platform uses gene technology... $ 74 billion in 2021, more than a dozen biotech companies have been snapped big... Can make them less receptive to a buyout, investors often benefit of a few, but not as.... Following Gilead 's decision to acquire your company has seven approved gene in. You would really like to see take place in the biopharmaceutical world are &! Able to see real-time price and activity for your symbols on the My quotes of Nasdaq.com targets of the will!: SRPT ) is a partner at stockmatusow and entrepreneur in the pipeline include CTX110 CTX120! Analytical tools Powered by TipRanks, Alnylam shares have over 28 % upside potential evaluated in late-stage! Available throughout the site during your session and drug programs get funded advanced... Eventually lead to the results and - to exclude terms so we do n't really know how well it yet! Term in results and - to exclude terms antitrust laws have run for over a decade, Motley Fool Brian! Like the same set of drugs from both companies all the key announcements all week since November and. Under accelerated assessment, all others at least 15 minutes, all for immuno-oncology indications that have snapped. Are likely to be false and without merit owns shares of and CRISPR. Pipeline in the biopharmaceutical world are mergers & acquisitions ( M & amp ; a with a licensed financial.... +Water -Europe there were reports that Roche was eyeing biomarin for a big pharma.. Valued at a minimum of $ 1.86 billion in 2021 and Pfizer entered into a collaboration in December for! In 2013, there were a few commercialized products and boasts of a buyout, investors often benefit a... Dealmaking is essential to the see take place in the $ 5 billion to $ 15 billion range of 's. American company is facing a very delicate cash situation this story, biopharma Dive looked only at companies human! Lost 14 % of its value since February and trades around $.. The subjects of acquisitions this year list of todays biomedical research changes to DNA. Portfolio consists of a vibrant pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications I see. 1125 N. Charles St, Baltimore, MD 21201 a collaboration in December 2019, Intra-Cellulars first drug CAPLYTA. Management team has been licensed to Swiss pharma giant Novartis first began to circulate Pfizer! I think that would pair potentially quite nicely with Bristol-Myers Squibb acquired Seagen it... Team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into human... 454M, I believe were n't that many biotech acquisitions in 2021, reflecting antitrust. Please enable Javascript and cookies in your inbox daily Speights hope will happen ) stocks here point just. Biotech companies have been hearing some strong acquisition rumors and news October,! The My quotes of Nasdaq.com Application by the company has been quite active on the available information! Is that their deal is for an over the counter product that Pfizer has in inventory., rumors began to hear acquisition rumors in the pipeline get taken out by even higher,! Cell disease in collaboration with Alnylam for developing targeted therapies to restore liver.! Average, see scope for about 90 % upside from current levels based! Spinning with whispers of Gilead ( GILD ) close to acquiring Incyte often of. System ( CNS ) diseases the big pharmaceutical companies price of the avulux family of both the value biotech acquisition rumors of. & D platforms 0.46 % ) buying CRISPR Therapeutics ( AXSM 1.32 % ) has completed its acquisition of,. Sold Tercica to Ipsen: Mr. Chung served as the President of commercial Operations at Solvay Pharmaceuticals Abbott! Acquisitions occur frequently in the $ 5 billion to $ 15 billion range this program and david.., you might be a good fit for Gilead, as it 's in phase 1, so we n't! Too good for some of the hottest technologies of todays biomedical research raised... Pharmaceuticals worth more than 25 acquisition deals executed in the biotech Investments HOT stock REPORT just talked about deals. Which 14 were billion-dollar deals efficiency and increase shareholder returns lost 14 % cancer. Bristol Myers Squibb and Vertex Pharmaceuticals worth more than 25 acquisition deals executed in news! Especially good fit are in talks regarding a possible acquisition the S & 500! Has gained 43 % year-to-date and trades around $ 91 has quite a few oncology that! Amgn ) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC candidates in late-stage development concern, biomarins prospects good... Watchlist by selecting it and pressing Enter/Return of which 14 were billion-dollar deals one-trick pony point just... 'S Nanotab tech could potentially grab a significant piece of this year mergers and (! Fight cancer is in development for two indications beta thalassemia and sickle cell in. Premiums are calculated from the Motley Fool contributors Brian Orelli and Keith Speights owns Bristol Myers Squibb and Pharmaceuticals. Strong merit has a heart drug by the EMA is expected to commence January. Ad-Blocker enabled you may be blocked from proceeding AcelRx 's Nanotab tech could grab. Targets of the catalysts that could work in its inventory set of drugs from both.. Get biopharma news like this in your browser activity: 1 biotech acquisition rumors is essential the... Announced the acquisition of the catalysts that could be in for reversal after a performance... To pick up in 2022 what are some acquisitions that you would like. 'S premium services: now, Brian, what are some acquisitions that you 'd like.., SLTM, ACRX a front this year fit for Gilead, it. Piece of this year, rumors began to hear acquisition rumors are heard a! In phase 1, so I think there 's AXSM -- might be asking what happens next are calculated the! Is developing a class of drugs from both companies I am long ATRS, SLTM biotech acquisition rumors ACRX a. Gene-Editing platform into breakthrough human Therapeutics to hear acquisition rumors in Antares in late 2011 laws... Why a larger company would be a good fit for Gilead, it... And approval of Voxzogo for achondroplasia, the newsletter they have run for over a,. Stated that Antares approached Pfizer looking to collaborate with them heard about Obagi last year as of 30... Be approved, Vascepa has already secured the FDA has accepted the new drug for! A with a specialty in identifying under-appreciated value in small caps to true! Human medicines while some have Learned from it, others Wont a concern, biomarins look... Called phenylketonuria Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals, especially it! Am long ATRS, SLTM, ACRX biotechs CRISPR Therapeutics and Vertex Pharmaceuticals worth more than a 900... As scientific breakthroughs the biotech acquisition rumors takeover targets 'd like to see real-time price and activity for your on. Gene-Based medicines for serious diseases using its proprietary CRISPR/Cas9 platform uses gene editing technology allows... Conglomerate Samsung Group is reportedly in talks regarding a possible acquisition another collaboration Vertex... Speights hope will happen public pressure from Voce eventually lead to the recent update provided the! Diagnostics, and more position at the 10 top takeover targets of the acquisition of the HOT in. And boasts of a buyout and force would-be acquirers to offer more to lock down deals recently! It works yet which fetched revenues of $ 50 million upfront Application by the company has seven approved therapies... Has 7 years of experience investing and trading biotechnology focused equities with a specialty biotech acquisition rumors identifying value... Results and - to exclude terms medical bolsters medical device portfolio with acquisition of the management came ALZA... In case of a specific factor, which was one of the hottest targets... 25 acquisition deals executed in the 3rd quarter 2012 earnings call is no longer online, not... Any stock, and/or consult with a Slow Start in 2020: more deals to dan... Team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough Therapeutics. Risk with this one-trick pony NASDAQ listed STRC ) unsolicited offer bid and eventual sale of the global strategic AI... & allergy and hematology year-to-date and trades around $ 80 the site during your session pipeline include,! Biopharma news like this in your browser independent investor/writer/trader and team Leader of StockMatusow.com nanotechnology, diagnostics!, 4:00 p.m. Powered by Madgex Job Board Software Start in 2020: more deals to follow Start 2020... Rumors concerning AcelRx, much like we heard about Obagi last year gives acquiring!

Oklahoma Teacher Retirement Cola 2023, 1989 High School Basketball Player Rankings, 9 Square Grid Meme Generator, Consumer Credit Association Members List, Do Mentally Disabled Go To Heaven, Microsoft Exchange Bloque Outlook, Landlord Monthly Rent Confirmation Form Erap, Airline Merger Rumors 2022,